FDA Accepts BridgeBio's Encaleret NDA with May 2027 PDUFA Date, Paving Way for First-in-Class ADH1 Therapy
BBIO sits 96% above its 52-week low of $42.09.
Summary
The FDA has accepted BridgeBio's NDA for encaleret in ADH1, with a PDUFA date of May 8, 2027. No advisory committee is planned, and the company is preparing for a potential launch of the first approved therapy for this genetic condition.
Key Events · Product Development and Regulatory · BBIO
-
FDA Accepts Encaleret NDA
The FDA accepted BridgeBio's New Drug Application for encaleret for ADH1, assigning a PDUFA target action date of May 8, 2027. No advisory committee meeting is currently planned.
-
First-in-Class Opportunity
If approved, encaleret would be the first therapy specifically indicated for ADH1, a genetic form of hypoparathyroidism affecting over 2,100 diagnosed U.S. patients. BridgeBio views it as a potential blockbuster.
-
Regulatory Path De-Risked
The FDA's decision not to hold an advisory committee removes a key uncertainty from the review process, suggesting a straightforward path to potential approval.
-
Global Expansion Plans
BridgeBio intends to submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2026, and is enrolling a pediatric study (CALIBRATE-PEDS) while planning a Phase 3 trial in chronic hypoparathyroidism (RECLAIM-HP).
Analysis · BBIO · Life Sciences
A major regulatory milestone has been reached with the FDA's acceptance of BridgeBio's NDA for encaleret in ADH1, setting a PDUFA date of May 8, 2027. The drug faces no approved competition and targets a growing diagnosed population of over 2,100 U.S. patients. Importantly, the filing confirms that no advisory committee is planned, removing a key uncertainty. A European submission is also on track for the second half of 2026, while the program expands into pediatric ADH1 and chronic hypoparathyroidism—moves that could significantly broaden the commercial opportunity. This news arrives amid strong recent execution, including positive Phase 3 data, a $1B financing, and multiple pipeline advances, reinforcing encaleret's potential as a blockbuster and a key value driver for the company.
At the time of this filing, BBIO was trading at $82.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2B. The 52-week trading range was $42.09 to $93.42. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.